Gossamer Bio Inc
NASDAQ:GOSS 4:00:00 PM EDT
| Market Cap (Intraday) | 288.67M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.27 |
| 50-Day MA | $1.19 |
| 200-Day MA | $1.04 |
Gossamer Bio Inc Stock, NASDAQ:GOSS
3115 Merryfield Row, Suite 120, San Diego, California 92121
United States of America
Phone: +1.858.684.1300
Number of Employees: 145
Description
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.